TPX-115
Phase 3Biologic
TPX-115 is one of 20 biologic programs targeting Nasolabial Folds. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Rotator Cuff Tear
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Valium
Akero TherapeuticsApproved
Neurontin
VViatris Specialty LLC
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Ultram
WWim Janssens
Approved
Marcaine
IInnocoll
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Suboxone
IIndivior Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rotator Cuff Tear3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TPX-115. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- TTego Science, Inc.